|
the mutation found to be indicative of EGFR inhibitor efficacy/inefficacy
is KRAS, but that research was done on/only holds for lung cancer and breast cancer is not just another puppy in the litter but a whole 'nother breed! Noone has done the research to see if that holds in other cancers as far as I can determine (from wide-ranging reading of the literature and conference attendance)
Glad you reiterated that you are NED--the way to be.
Will they be confirming that your brain met was also ER- and PR---otherwise Faslodex might be considered, wouldn't you think?
Again, congratulations on the NED
|